Logo

Henlius Presents Results of HLX04 (biosimilar- bevacizumab) in P-III Study at ESMO Asia 2020

Share this

Henlius Presents Results of HLX04 (biosimilar- bevacizumab) in P-III Study at ESMO Asia 2020

Shots:

  • The P-III HLX04-mCRC03 study involves assessing the efficacy- safety and immunogenicity of HLX04 vs reference bevacizumab (7.5 mg/kg- q3w or 5 mg/kg- q2w) + CT (Xelox or mFOLFOX6) as a 1L treatment in patients in the ratio of (1:1) with mCRC
  • Result: PFSR36wk (46.4% vs 50.7%); no significant difference b/w the treatment groups in 2EPs including OS- PFS- ORR- TTR and DoR; safety and immunogenicity profiles were similar b/w HLX04 and the reference
  • The NMPA has accepted the NDA for HLX04. Additionally- Henlius has submitted a patent for a new formulation of HLX04 with potential better safety and stability- designed for ophthalmic use

Click Here ­ Ref:  Henlius | Image:  Henlius

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions